Tiverton Asset Management’s Iterum Therapeutics ITRM Stock Holding History

Tiverton Asset Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$664K	Sell	7,504 -327	-4%	-$31.8K	0.02%	346
2019 Q2	$808K	Sell	7,831 -1,532	-16%	-$170K	0.03%	301
2019 Q1	$1.13M	Hold	9,363	–	–	0.05%	228
2018 Q4	$703K	Hold	9,363	–	–	0.04%	210
2018 Q3	$941K	Hold	9,363	–	–	0.05%	204
2018 Q2	$1.53M	Buy	+9,363	New	+$1.69M	0.08%	148

Other funds holding ITRM

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return

FCM

Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

TAM

Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return

Tiverton Asset Management's ITRM Position: Q3 2019 in Review

Tiverton Asset Management reduced its Iterum Therapeutics (ITRM) stake by 4.2% in Q3 2019, selling an estimated $31.8K and leaving 7,504 shares worth $664K. The position accounts for 0.02% of the portfolio, ranked #346.

Tiverton Asset Management first reported a position in ITRM in Q2 2018 and has held it in 6 quarters since. The position peaked at $1.53M in Q2 2018. 19 funds tracked by Wall St. Rank hold ITRM as of Q3 2019.

Tiverton Asset Management held 7,504 shares of Iterum Therapeutics worth $664K as of Q3 2019.
Tiverton Asset Management sold 327 Iterum Therapeutics shares in Q3 2019, an estimated $31.8K.
Iterum Therapeutics made up 0.02% of Tiverton Asset Management's portfolio in Q3 2019, its #346 holding.
Tiverton Asset Management first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 6 quarters since.
Tiverton Asset Management's Iterum Therapeutics position peaked at $1.53M in Q2 2018.
19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.